Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 11
Phase 22

Trial Status

Recruiting1
Other3

Role Distribution

Principal Investigator4
PI Rate100%

Activity Timeline

Research Network

Collaboration Network

27 collaborators·41 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Research Areas & Affiliations

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Jiafei Chen

Putian First Hospital

Similar
1 trials

Shared therapeutic areas:

AdebrelimabBevacizumabCarcinoma, Hepatocellular+2 more

Worked with same sponsors:

Jiangsu HengRui Medicine Co., Ltd.The First Affiliated Hospital of Xiamen University
Collaborated on 1 trial
Similarity Score54%

Yongzhong Wang

Sanming Second Hospital

Similar
1 trials

Shared therapeutic areas:

AdebrelimabBevacizumabCarcinoma, Hepatocellular+2 more

Worked with same sponsors:

Jiangsu HengRui Medicine Co., Ltd.The First Affiliated Hospital of Xiamen University
Collaborated on 1 trial
Similarity Score54%

Jianbo Chen

The First Affiliated Hospital of Xiamen University

Similar
1 trials

Shared therapeutic areas:

AdebrelimabBevacizumabCarcinoma, Hepatocellular+2 more

Worked with same sponsors:

Jiangsu HengRui Medicine Co., Ltd.The First Affiliated Hospital of Xiamen University
Collaborated on 1 trial
Similarity Score54%

Qinghe Cai

The Affiliated Hospital of Putian University

Similar
1 trials

Shared therapeutic areas:

AdebrelimabBevacizumabCarcinoma, Hepatocellular+2 more

Worked with same sponsors:

Jiangsu HengRui Medicine Co., Ltd.The First Affiliated Hospital of Xiamen University
Collaborated on 1 trial
Similarity Score54%

congren Wang

Quanzhou First Hospital

Similar
1 trials

Shared therapeutic areas:

AdebrelimabBevacizumabCarcinoma, Hepatocellular+2 more

Worked with same sponsors:

Jiangsu HengRui Medicine Co., Ltd.The First Affiliated Hospital of Xiamen University
Collaborated on 1 trial
Similarity Score54%

Feng Lin

Ningde Mindong Hospital

Similar
2 trials

Shared therapeutic areas:

Carcinoma, HepatocellularAdebrelimabBevacizumab+2 more

Worked with same sponsors:

Jiangsu HengRui Medicine Co., Ltd.The First Affiliated Hospital of Xiamen University
Collaborated on 1 trial
Similarity Score54%

You Lu, MD

West China Hospital

Related
18 trials

Shared therapeutic areas:

Advanced Solid TumorsSolid Tumor

Worked with same sponsors:

Jiangsu HengRui Medicine Co., Ltd.
Similarity Score8%

Alice P Chen, M.D.

National Cancer Institute (NCI)

Related
18 trials

Shared therapeutic areas:

Advanced Solid TumorsSolid Tumor
Similarity Score8%

Zhenfeng Zhang, MD, PhD

Second Affiliated Hospital of Guangzhou Medical University

Related
21 trials

Shared therapeutic areas:

Carcinoma, HepatocellularSolid Tumor
Similarity Score8%

Aung Naing, Md

M.D. Anderson Cancer Center

Related
16 trials

Shared therapeutic areas:

Solid TumorAdvanced Solid Tumors
Similarity Score8%

Publications (0)

No publications found for this investigator.

Clinical Trials (4)

Showing 4 of 4 trials

NCT05970666Phase 2PrincipalInvestigator

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

AdebrelimabBevacizumabHepatocellular Carcinoma+2 more
Recruiting
NCT06220318Phase 1/2PrincipalInvestigator

Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors

Solid Tumor
Active Not Recruiting
NCT07438093Not ApplicablePrincipalInvestigator

Safety, Tolerability, and Preliminary Efficacy of Peginterferon α-2b in Combination With an Anti-PD-1 Antibody in Patients With Advanced or Metastatic Malignant Solid Tumors

Advanced Solid Tumors
Not Yet Recruiting
NCT07780539PrincipalInvestigator

Real-World Study of the Safety and Efficacy of Surufatinib in the Treatment of Neuroendocrine Tumors

Neuroendocrine (NE) Tumors
Not Yet Recruiting

All 4 trials loaded